Adimab Stock

Adimab is an antibody discovery and optimization platform, developing full-length human Immunoglobulin Gs.

Sign up today and learn more about Adimab Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Adimab Stock

Adimab's integrated antibody discovery and optimization platform provides unprecedented speed from antigen to purified, full-length human IgGs. Adimab offers fundamental advantages by delivering diverse panels of therapeutically relevant antibodies that meet the most aggressive standards for affinity, epitope coverage, species cross-reactivity and expressability. Adimab enables its partners to rapidly expand their biologics pipelines through a broad spectrum of technology access arrangements.

Funding History

July 2007$6.2M
July 2007$2K
September 2007$5.9M
March 2008$3.2M
November 2008$4.0M
January 2010$8.2M
December 2010$4.0M
April 2012$14.0M


General Counsel

Philip Chase


Colin Greenspon

VP, Head, Business Development

Guy Van Meter

Co-founder, Chair of the SAB

K. Dane Wittrup

Board Member

Tillman Gerngross

Founder, CEO

Tillman Gerngross

Board of Directors

Carl L. Gordon

Member of the Board of Directors

Bill Maris

VP Computational Biology

Max Vasquez

Chief Scientific Officer

Eric Krauland

Director, Open Innovation

Piotr Bobrowicz


Errik Anderson

Member of the Board of Directors

Terrance McGuire


EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: